Korro Bio Inc expected to post a loss of $2.61 a share - Earnings Preview

Reuters
2024-10-30

* Korro Bio Inc is expected to show no change in quarterly revenue when it reports results on October 31 (estimated) for the period ending September 30 2024

*

* ​LSEG's mean analyst estimate for Korro Bio Inc is for a loss of $2.61 per share.

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

* The mean earnings estimate of analysts was unchanged in the last three months. ​

* Wall Street's median 12-month price target for Korro Bio Inc is 120.00​, above​ its last closing price of $63.85. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI

ENDING ARTESTIMAT ESTIMATE MET, SE %

E® MISSED

Jun. 30 2024 -2.40 -2.39 -2.43 Missed -1.5

Mar. 31 2024 -2.49 -2.51 -2.44 Beat 2.8

Dec. 31 2023 -2.57 -2.36 -25.65 Missed -985.3

Jan. 1 0001 -16.50 -17.72 -15.50 Beat 12.6

​​Jun. -17.34 -17.76 -15.00 Beat 15.6

30 2023

Mar. 31 2023 -20.50 -21.02 -27.50 Missed -30.8​

Dec. 31 2022 -28.50 -31.54 -24.50 Beat 22.3

Sep. 30 2022 -27.97 -28.46 -27.50 Beat 3.4

This summary was machine generated October 29 at 21:05 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10